Novel protein glycan-derived markers of systemic inf lammation and c-reactive protein in relation to glycemia, insulin resistance, and insulin secretion

Diabetes Care

Volumn 40, Issue 3, 2017, Pages 375-382

  Lorenzo, Carlos ^a   Festa, Andreas ^b   Hanley, Anthony J ^c,d   Rewers, Marian J ^e   Escalante, Agustin ^a   Haffner, Steven M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GALACTOSAMINE; INSULIN; N ACETYLGLUCOSAMINE; SIALIC ACID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; POLYSACCHARIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL ACTIVITY; SMOKING; BLOOD; BODY MASS; CHEMISTRY; CROSS-SECTIONAL STUDY; GLUCOSE TOLERANCE TEST; METABOLISM; SECRETION (PROCESS); STATISTICAL MODEL;

ACETYLGLUCOSAMINE; BIOMARKERS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GALACTOSAMINE; GLUCOSE TOLERANCE TEST; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; POLYSACCHARIDES;

EID: 85019701932     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1569     Document Type: Article

References (40)

1. Festa A, DAgostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47
2. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
3. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men. Circulation 2008;118: 2243-2251, 4p following 2251
4. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 2006; 126:855-867
5. Lauc G. Sweet secret of the multicellular life. Biochim Biophys Acta 2006;1760:525-526
6. Bell JD, Brown JC, Nicholson JK, Sadler PJ. Assignment of resonances for "acute-phase" glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett 1987;215:311-315
7. Otvos JD, Shalaurova I, Wolak-Dinsmore J, et al. GlycA: A composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem 2015;61:714-723
8. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc 2014;3:e001221
9. Duprez DA, Otvos J, Sanchez OA, Mackey RH, Tracy R, Jacobs DR Jr. Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clin Chem 2016;62:1020-1031
10. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334
11. Festa A, DAgostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes 2002;51:1131-1137
12. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan sidechain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2015;35:1544-1550
13. Connelly MA, Gruppen EG, Wolak-Dinsmore J, et al. GlycA, amarker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta 2016;452:10-17
14. Wagenknecht LE, Mayer EJ, RewersM, et al. The Insulin Resistance Atherosclerosis Study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 1995;5:464-472
15. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985;6:45-86
16. Steil GM, Volund A, Kahn SE, Bergman RN. Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes 1993;42:250-256
17. Pacini G, Bergman RN. MINMOD: A computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 1986;23: 113-122
18. Smith KD, Pollacchi A, Field M, Watson J. The heterogeneity of the glycosylation of alpha-1-Acid glycoprotein between the sera and synovial fluid in rheumatoid arthritis. Biomed Chromatogr 2002;16:261-266
19. Ritchie SC, Würtz P, Nath AP, et al. The biomarker GlycA is associated with chronic inflammation and predicts long-Term risk of severe infection. Cell Syst 2015;1:293-301
20. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
21. Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes: A systematic review and meta-Analysis. Diabetes Care 2013; 36:166-175
22. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: Time to start. Nat Rev Drug Discov 2014;13:465-476
23. Gornik O, Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers 2008;25:267-278
24. Belalcazar LM, Reboussin DM, Haffner SM, et al.; Look AHEAD Research Group. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 2010;33:2297-2303
25. Haffner S, Temprosa M, Crandall J, et al.; Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-1572
26. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003;289:1799-1804
27. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830
28. Wu H, Ghosh S, Perrard XD, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007;115:1029-1038
29. Carroll JF, Fulda KG, Chiapa AL, et al. Impact of race/ethnicity on the relationship between visceral fat and inflammatory biomarkers. Obesity (Silver Spring) 2009;17:1420-1427
30. Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, et al.; SWAN Investigators. Ethnic differences in C-reactive protein concentrations. Clin Chem 2008;54:1027-1037
31. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Womens Health Study). Am J Cardiol 2004;93:1238-1242
32. Hyatt TC, Phadke RP, Hunter GR, Bush NC, Muñoz AJ, Gower BA. Insulin sensitivity in African-American and white women: Association with inflammation. Obesity (Silver Spring) 2009;17:276-282
33. Ford ES, Giles WH, Myers GL, Mannino DM. Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999-2000. Clin Chem2003;49:686-690
34. Khera A, McGuire DK, Murphy SA, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005;46:464-469
35. Albert MA, Ridker PM. C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference? Circulation 2006;114: e67-e74
36. Fr öhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003;24:1365-1372
37. Kuller L, Tracy R, Shaten J, Meilahn EN. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-547
38. Ohsawa M, Okayama A, Nakamura M, et al. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-Term smoking cessation in male smokers. Prev Med 2005;41:651-656
39. Imhof A, Fröhlich M, Loewel H, et al. Distributions of C-reactive protein measured by highsensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 2003;49:669-672
40. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003;49: 1258-1271